Published in final edited form as:

J Am Chem Soc. 2009 November 25; 131(46): 16663–16665. doi:10.1021/ja907045h.

Small Molecule Modulators of Copper-Induced A β Aggregation

Sarmad S. Hindo¹, Allana M. Mancino¹, Joseph J. Braymer¹, Yihong Liu¹, Subramanian Vivekanandan², Ayyalusamy Ramamoorthy², and Mi Hee Lim¹

¹Department of Chemistry and the Life Sciences Institute, University of Michigan, Ann Arbor, Michigan, 48109

²Biophysics and Department of Chemistry, University of Michigan, Ann Arbor, Michigan, 48109

The World Health Organization estimates that *ca.* 11 million people worldwide have Alzheimer's disease (AD) and this population is expected to nearly double by 2030.¹ This disease, which manifests in progressive neurodegeneration, is characterized by the presence of amyloid- β (A β) peptide aggregates.^{2–4} The mechanism for the formation of A β aggregates is not entirely understood, though metal ions such as Cu^{II} and Zn^{II} have been shown to facilitate A β aggregation.^{2–4} In particular, redox-active Cu^{II} is implicated in the generation of reactive oxygen species (ROS), leading to an increase in oxidative stress, which is one proposed neuropathology of AD.^{2–8} To elucidate Cu-mediated events in AD pathogenesis, Cu coordination to A β has been explored as well as effects on the removal of Cu from Cu-A β species using chelating agents.^{2–13} These studies have demonstrated that the extent of metal-induced A β aggregation and ROS production can be modulated by metal chelators, which highlights metal-ion chelation therapy as a promising AD treatment.

Many orthodox metal chelators show inhibition of metal-induced A β aggregation and ROS formation,^{2–4,9–13} but they may not be suitable for AD therapeutics. Most of these chelators cannot cross the blood brain barrier (BBB) and are not able to specifically target metal ions in various A β forms without removing vital metals from other biological systems due to lack of an A β recognition ability. The metal chelator clioquinol (CQ) reveals decreased A β aggregate deposits and improved cognition in early clinical trials.¹⁴ The long-term use is, however, limited by an adverse side effect, subacute myelo-optic neuropathy.^{15–16} Our recent studies suggest that CQ assists, in part, in the disaggregation of A β aggregates, but could not completely prevent A β aggregation.¹⁷ Therefore, rational design of chelating agents capable of targeting metal ions in A β species followed by modulation of A β aggregation in the brain is essential toward metal-ion chelation therapy for AD. Only limited efforts have been made toward this goal.^{3,10–12} Herein we present the preparation of bifunctional metal chelators (**1** and **2**) and their interaction with Cu-induced A β aggregates. Both chelators exhibit modulation of Cu-associated A β aggregation, which is more effective than that by the well-known metal chelating agents CQ, EDTA, and phen in this study.¹⁸

Our strategy for developing metal chelators as potential AD therapeutics is to create bifunctional molecules that contain structural moieties for metal ion chelation and A β recognition (Figure 1). For the latter purpose, the basic frameworks of **1** and **2** are based on the A β aggregate-imaging probes ¹²⁵IMPY and *p*-¹²⁵I-stilbene,¹⁸ respectively, which show strong binding affinity to A β aggregates.¹⁹ These compounds are small, neutral, lipophilic, and thus able to penetrate the BBB. Furthermore, they are easily removed from normal brain

mhl@umich.edu .

Supporting Information Available: Experimental procedures, preparation and characterization of **1** and **2**, Table S1, Scheme S1, and Figures S1 - S8. This material is available free of charge via the Internet at <http://pubs.acs.org>.

tissue and accumulate in the blood at relatively low levels, which reduces their toxicity for in vivo applications.¹⁹ For metal chelation, we incorporate a nitrogen and/or oxygen donor atom into the A β aggregate-imaging agents (Figure 1). Similar approaches have been described by other groups which have used the structure of a probe for detecting A β aggregates, thioflavin-T (ThT),²⁰ as an A β recognition moiety.¹¹⁻¹² The chelators, however, were composed of truncated structures for A β identification and/or non-specific metal binding sites. Our design principle for chelators involves the direct introduction of a metal coordination site into an A β recognition molecule without major structural modifications.

Defined by the restrictive terms of Lipinski's rules (MW < 450, clogP < 5, HBD < 5, and HBA < 10), PSA (< 90 Å²), and calculated logBB for potential applications in brains,²¹ **1** and **2** fulfill drug-like criteria and possible brain penetration (Table S1). The metal chelators **1** and **2** were prepared *via* cyclocondensation and Schiff base condensation, respectively (Scheme S1, Supporting Information). The binding stoichiometry of **1** and **2** with CuCl₂ was determined by Job's method of continuous variation using UV-visible spectroscopy.²³ The Job plot for **1** revealed a break between 0.33 and 0.5, indicating the formation of a mixture of 1:2 and 1:1 Cu:ligand complexes (Figure S1). For **2**, the break occurred at 0.5, suggesting the generation of a 1:1 Cu:ligand complex.

In addition to metal binding properties of **1** and **2**, their direct interactions with A β were investigated via two-dimensional TROSY ¹H-¹⁵N HSQC-based NMR structural determinations (TROSY = transverse relaxation optimized spectroscopy; HSQC = heteronuclear single quantum correlation).²⁴ The TROSY spectrum of A β itself is consistent with the previously reported one.^{24b} Interestingly, upon treatment with **1** or **2**, chemical shifts of the A β residues E11 and H13 are significantly shifted, as depicted in Figures 2 and S2. Both **1** and **2** show more influence on the less ordered, *N*-terminal portion of A β than the C-terminus, which is clearly presented in plots displaying the difference of ¹H-¹⁵N shifts ($\Delta\delta$ Hz) as a function of the amino acid sequence (Figures 2b and S2b). These observations reveal that **1** and **2** are capable of recognizing A β and, more importantly, they could have close contact with metal coordination sites in A β , where H6, H13, and H14 residues are involved.^{2-8,25} This suggests that **1** and **2** may target easily metal ions in A β species. Along with NMR studies, the competitive binding of **1** to A β aggregates with ThT, a fluorescent indicator for A β species upon binding, was observed (Figure S3),²⁶ which suggests that **1** is able to bind to A β . Taken together, these studies by NMR and fluorescence demonstrate interactions of **1** or **2** with A β , and thus, these compounds would be classified as bifunctional molecules for metal chelation as well as A β recognition.

To investigate the influence of **1** and **2** on Cu^{II}-induced A β aggregation, we performed two individual studies (Scheme 1): inhibition (the prevention of forming metal-induced A β aggregates) and disaggregation (the transformation of metal-A β fibrils by chelators). The degree of A β aggregation was probed mainly by transmission electron microscopy (TEM).²⁷

For the inhibition studies (Scheme 1 and Figure 3), A β peptide (25 μ M) was treated with 1 equivalent of Cu^{II} for 2 min at room temperature followed by incubation with a chelator (50 μ M) for 24 h at 37 °C with constant agitation. The Cu^{II}-induced A β aggregation is modulated by treatment with **1** or **2** (Figure 3b,c). Less Cu^{II}-triggered A β aggregation is indicated in the presence of **1** and **2** over the well-known chelators CQ, EDTA, and phen (Figure 3b-f). Even upon treatment with the chelators CQ, EDTA, and phen, development of A β aggregates is still visible, but their morphology is different from that of Cu^{II}-A β aggregates (Figure 3a). These observations suggest that metal chelation by these compounds may be one of the driving forces to alter structural organization of A β .

aggregates. Our previous studies reveal that CQ is capable of chelating metal ions from metal-A β aggregates, but it does not prevent completely A β aggregation.¹⁷ Furthermore, the control molecules MPY and stilbene that do not contain a metal binding site, but interact with A β species, also exhibit A β aggregation (Figure 3g,h). Like other chelators, conformational transformation of A β species is observed by MPY and stilbene (Figure 3g,h). This may be resulted from interactions of A β with MPY or stilbene, suggesting the direct A β contact as an important parameter for modulation of A β aggregation. Overall, based on these TEM results using the control molecules and the known chelators, interaction with either only A β or only Cu^{II} is not sufficient to block the A β aggregation. Synergistic interactions of **1** and **2** with A β and Cu^{II} could result in better modulation of A β aggregation, as described in our design strategy.

Along with the TEM analysis, the A β species from the inhibition experiments were visualized by native gel electrophoresis followed by Western blotting using an anti-A β antibody 6E10 (Figure S5).²⁸ In the samples of Cu^{II}-A β incubated with **1** or **2**, low molecular weight A β species are shown, while the samples containing CQ, phen, and EDTA indicate only transformation of A β to high molecular weight A β species. Thus, these observations also support that modulation of Cu^{II}-induced A β aggregation can be better obtained using small molecules having bifunctionality for metal chelation and A β interaction.

For the disaggregation studies (Scheme 1 and Figure S6), a chelator (50 μ M) was added to A β fibrils generated by reacting A β with 1 equivalent of Cu^{II} (25 μ M) for 24 h at 37 °C with constant agitation. Compounds **1** and **2** induce more disaggregation of A β fibrils, compared to CQ,¹⁷ phen, and EDTA (Figure S6). These results show that **1** and **2** are capable of disassembling the well-structured A β fibrils.

The effects of the chelators on the generation of H₂O₂ by Cu-bound A β was examined in cell-free solutions using a horseradish peroxidase (HRP)/Amplex Red assay.^{6,7} Samples containing Cu^{II}, A β , and either **1** or **2** show 70% lower [H₂O₂] (Figure S7), revealing that **1** and **2** can reduce H₂O₂ production by Cu-A β . As expected, the sample containing A β , Cu^{II} and phen in the presence of ascorbate as a reducing agent produces significant amount of H₂O₂, compared to that of Cu-A β , since the Cu^{2+/+} redox cycle can be supported by phen.²⁹ Lastly, the ability of **1** and **2** to modulate the Cu-induced A β aggregation was investigated in human neuroblastoma cells (SK-N-BE(2)-M17). The chelators **1** and **2** exhibit less toxicity than the clinically available compound CQ in the presence of Cu^{II} (Figure 4). Also, **2** shows no toxicity up to 200 μ M (Figure S8). Importantly, toxicity arising from Cu-A β is diminished upon incubation with **2**, affording *ca.* 90% cell survival. This is a better survival rate than for other chelators including CQ (Figure 4). These observations suggest that **2** may be a good candidate to be further studied in vitro and in vivo.

In summary, in order to specifically target divalent metal ions in A β aggregates, two chelators, **1** and **2**, were prepared based on a design strategy that integrates metal binding properties into A β imaging agents without major structural modifications. The bifunctionality for metal chelation and A β interaction of **1** and **2** was verified by spectroscopic investigations. These bifunctional molecules modulate the generation of Cu-triggered A β aggregates and promote their disaggregation. Furthermore, studies of our chelators in living cells demonstrate their ability to regulate cytotoxicity of Cu-induced A β species and prompt further investigations in vitro and in vivo. Our novel approach may lead to new alternatives for multifunctional chelators for metal-ion chelation therapy in AD.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by the University of Michigan (to M.H.L.) and NIH (DK078885, to A.R.). We thank Dr. Jeffrey Brender and Ravi Nanga for assistance with NMR and Akiko Kochi and Thu Truong for experimental assistance. We are grateful to Professor Jason Gestwicki, Ms. Ashley Reinke and Dr. Christopher Evans for helpful discussions and suggestions.

References

1. Neurological disorders. 1st ed.. World Health Organization; 2007.
2. Rauk A. Chem. Soc. Rev. 2009; 38:2698–2715. [PubMed: 19690748]
3. (a) Bush AI. Neurobiol. Aging. 2002; 23:1031. [PubMed: 12470799] (b) Barnham KJ, Masters CL, Bush AI. Nat. Rev. Drug Discovery. 2004; 3:205. (c) Barnham KJ, Bush AI. Curr. Opin. Chem. Biol. 2008; 12:222. [PubMed: 18342639]
4. Molina-Halagado F, Hider RC, Gaeta A, Williams R, Francis P. Biometals. 2007; 20:639–654. [PubMed: 17294125]
5. Syme CD, Nadal RC, Rigby SEJ, Viles JH. J. Biol. Chem. 2004; 279:18169–18177. [PubMed: 14978032]
6. Hureu C, Faller P. Biochimie. 2009 DOI: 10.1016/j.bichi.2009.03.013.
7. Himes RA, Park GY, Siluvai GS, Blackburn NJ, Karlin KD. Angew. Chem. Int. Ed. 2008; 47:9084.
8. (a) Karr JW, Kaupp LJ, Szalai VA. J. Am. Chem. Soc. 2004; 126:13534. [PubMed: 15479110] (b) Shearer J, Szalai VA. J. Am. Chem. Soc. 2008; 130:17826. [PubMed: 19035781]
9. Raman B, Ban T, Yamaguchi K.-i. Sakai M, Kawai T, Naiki H, Goto Y. J. Biol. Chem. 2005; 280:16157. [PubMed: 15718230]
10. (a) Schugar H, Green DE, Bowen ML, Scott LE, Storr T, Bohmerle K, Thomas F, Allen DD, Lockman PR, Merkel M, Thompson KH, Orvig C. Angew. Chem. Int. Ed. 2007; 46:1716. (b) Storr T, Merkel M, Song-Zhao GX, Scott LE, Green DE, Bowen ML, Thompson KH, Patrick BO, Schugar HJ, Orvig C. J. Am. Chem. Soc. 2007; 129:7453. [PubMed: 17511455]
11. Dedeoglu A, et al. Exp. Gerontology. 2004; 39:1641.
12. Rodriguez-Rodriguez C, Sanchez de Groot N, Rimola A, Alvarez-Larena A, Lloveras V, Vidal-Gancedo J, Ventura S, Vendrell J, Sodupe M, Gonzalez-Duarte P. J. Am. Chem. Soc. 2009; 131:1436. [PubMed: 19133767]
13. Chen T, Wang X, He Y, Zhang C, Wu Z, Liao K, Wang J, Guo Z. Inorg. Chem. 2009; 48:5801–5809. [PubMed: 19496588]
14. Ritchie CW, et al. Arch. Neurology. 2003; 60:1685.
15. Cahoon L. Nat. Med. 2009; 15:356. [PubMed: 19350001]
16. Arbiser JL, Kraeft S-K, Van Leeuwen R, Hurwitz SJ, Selig M, Dickersin GR, Flint A, Byers HR, Chen LB. Mol. Med. 1998; 4:665. [PubMed: 9848083]
17. Mancino AM, Hindo SS, Kochi A, Lim MH. Inorg. Chem. 2009 DOI: 10.1021/ic9014256.
18. Abbreviations: **1** = 2-(4-(dimethyl-amino)phenyl)imidazo[1,2-*a*]pyridine-8-ol; **2** = *N*¹,*N*¹-dimethyl-*N*⁴-(pyridin-2-yl-methylene)benzene-1,4-diamine; CQ = clioquinol; EDTA = 2,2',2'',2'''-(ethane-1,2-diyl dinitrilo)tetraacetic acid; phen = 1,10-phenanthroline; ¹²⁵IMPY = 4-(6-iodoimidazo[1,2-*a*]pyridin-2-yl)-*N,N*-dimethylaniline; *p*-¹²⁵I-stilbene = (*E*)-4-(4-iodostyryl)-*N,N*-dimethylaniline.
19. (a) Kung HF, Kung MP, Zhuang ZP, Hou C, Lee C-W, Plossl K, Zhuang B, Skovronsky DM, Lee VM-Y, Trojanowski JQ. Mol. Imag. Biol. 2003; 5:418. (b) Newberg AB, Wintering NA, Plossl K, Hochold J, Stabin MG, Watson M, Skovronsky D, Clark CM, Kung M-P, Kung HF. J. Nucl. Med. 2006; 47:748. [PubMed: 16644743] (c) Zhuang Z-P, Kung M-P, Wilson A, Lee G-W, Plossl K, Hou G, Holtzman DM, Kung HF. J. Med. Chem. 2003; 46:237. [PubMed: 12519062]
20. LeVine H. Methods in Enzymol. 1999; 309:274–284.

21. MW: molecular weight; clogP: calculated logarithm of the octanol-water partition coefficient; HBD: hydrogen-bond donor atoms; HBA: hydrogen-bond acceptor atoms; PSA: polar surface area; logBB: prediction of a brain penetration measure; see, (a) Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. *Adv. Drug Delivery Rev.* 1997; 23:3–25. (b) Clark DE, Pickett SD. *Drug Discovery Today*. 2000; 5:49–58. [PubMed: 10652455]
22. Saeed AAH, Matti GY. *Indian J. Chem.* 1979; 18B:338.
23. Huang CY. *Methods Enzymol.* 1982; 87:509.
24. Sodium dodecyl- d_6 sulfate (SDS) is employed in NMR studies of $A\beta$ in order to help solubility and decelerate aggregation. No $A\beta$ aggregation was observed on the time scale of our measurements; see (a) Shao H, Jao S, Ma K, Zagorski MG. *J. Mol. Biol.* 1999; 258:755–773. [PubMed: 9878442] (b) Jarvet J, Danielsson J, Damberg P, Oleszczuk M, Gräslund A. *J. Biomol. NMR.* 2007; 39:63–72. [PubMed: 17657567] (c) Mandal P,K, Pettegrew JW. *Biochim. Biophys. Acta.* 2008; 1778:2633–2639. [PubMed: 18639516]
25. Danielsson J, Pierattelli R, Banci L, Gräslund A. *FEBS J.* 2007; 274:46–59. [PubMed: 17222176]
26. For **2**, competitive binding experiment with ThT to $A\beta$ aggregates was not performed due to the interference of the absorption of **2** with the window for fluorescence analysis.
27. The absorptions of chelators and their corresponding metal complexes (Figure S4) interfere with the windows for fluorescence (ThT) and/or turbidity assays.^{9-13,17,28}
28. Reinke AA, Seh HY, Gestwicki JE. *Bioorg. Med. Chem. Lett.* 2009; 19:4952–4957. [PubMed: 19640715]
29. Lei Y, Anson FC. *Inorg. Chem.* 1994; 33:5003.

Figure 1. Strategy of designing metal chelators. Chemical structures of ¹²⁵IMPY, *p*-¹²⁵I-stilbene, CQ, **1**, and **2** are depicted.

Figure 2.

NMR studies of $\text{A}\beta$ with **2**. (a) Overlay of 2D TROSY ^1H - ^{15}N HSQC spectra of $\text{A}\beta$ upon addition of **2** (900 MHz, 200 mM SDS, 20 mM sodium phosphate, pH 7.3, 25 °C). Black and red chemical shifts were obtained from the $\text{A}\beta$ sample (^{15}N -labeled $\text{A}\beta_{1-40}$ was used, *ca.* 192 μM) containing *ca.* 2 μL of $\text{DMSO-}d_6$ or *ca.* 1.2 equivalent of **2** (*ca.* 1.4 μL $\text{DMSO-}d_6$), respectively. (b) Change in the combined ^1H and ^{15}N chemical shifts as a function as the amino acid sequence to identify the major interaction sites of $\text{A}\beta$ with **2**. * Denotes absent or overlapped signals.

Figure 3.

Inhibition experiments. TEM images of samples of Cu(II)-treated A β (a) incubated with the chelator [(b) **1**, (c) **2**, (d) CQ, (e) EDTA, or (f) phen] or with the control molecule [(g) MPY or (h) stilbene] ($[A\beta] = 25 \mu\text{M}$, $[Cu^{II}] = 25 \mu\text{M}$, $[\text{chelator}] = 50 \mu\text{M}$, 24 h, 37 °C, constant agitation). The scale bar indicates 500 nm.

Figure 4.

Cytotoxicity of Cu-associated A β with the chelators in SK-N-BE(2)-M17 cells using a MTT assay. Cell viability (%) with [chelator] (green), [the chelator and Cu^{II}] (blue), or [Cu^{II}, A β , and chelator] (orange) after 24 h incubation ([A β] = 20 μ M, [Cu^{II}] = 20 μ M, [chelator] = 40 μ M). Treatment of A β in the absence and presence of Cu^{II} for 24 h results in ~90 and ~70% survival of cells, respectively.

Scheme 1.

Experiments of inhibition and disaggregation.